

1626

08/06/2003 13:06 317-277-1917

ELI LILLY AND CO

PAGE 01/45

Fax

FAX RECEIVED

AUG 07 2003

GROUP 1600

Eli Lilly and Company  
Lilly Corporate Center  
Indianapolis, Indiana 46285  
U.S.A.

*Lilly*

To:

*Scanning Division*

Company:

*USPTO*

Fax:

*703-872-9306*

Date:

*August 06, 2003*

From:

*Francis Cinah*

Fax:

*317-277-1917*

Total Pages:

*Pat. Atty*

If you have any questions concerning the content of this message, please call:

*Please receive a copy of previously filed  
amendments for scanning.*

This facsimile message is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If you have received this facsimile in error, please notify us immediately by telephone (collect), and return the original message to us at the above address via U.S. Postal Service.

Answers That Matter.

Received from <317 277 1917> at 8/6/03 2:05:06 PM [Eastern Daylight Time]

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Arlington, VA 22202, on the date appearing below.  
ELI LILLY AND COMPANY

By Linda M. DunbarDate September 25, 2002

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	: Ho-Shen Lin, et al.	)	
Serial No.	: 10/018,037	)	
Filed	: December 11, 2001	)	Group Art Unit:
		)	1626
For	: sPLA2 Inhibitors	)	Examiner:
		)	G. Shameem
Docket No.	: X-12420	)	


AMENDMENT UNDER 37 C.F.R. 1.121

Assistant Commissioner for Patents  
Arlington, VA 22202  
Sir:

This Amendment is in response to the Office Action dated August 25, 2002, Paper No. 4. Please amend the application as follows:

In the Claims

1. (amended) An indole compound represented by the formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug derivative thereof;



wherein ;